The clinical impact of three validated PD-L1 immunohistochemistry assays as a prognostic factor in small cell lung cancer

BACKGROUND: Evidence of the clinical impact of programmed death-ligand 1 (PD-L1) expression in small cell lung cancer (SCLC) is scarce and conflicting, even though atezolizumab became the first PD-L1 inhibitor approved by the US Food and Drug Administration (FDA) in recent years for the initial trea...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Yong Seok, Lim, Jun Hyeok, Ryu, Wookyung, Park, Mi Hwa, Kim, Lucia, Kim, Kang, Kim, Woo Youl, Nam, Hae-Seong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8264325/
https://www.ncbi.nlm.nih.gov/pubmed/34295660
http://dx.doi.org/10.21037/tlcr-21-165

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8264325/
https://www.ncbi.nlm.nih.gov/pubmed/34295660
http://dx.doi.org/10.21037/tlcr-21-165

Ejemplares similares